Intrathecal Administration of Autologous Mesenchymal Stem Cells in Multiple System Atrophy – A Phase I/II Dose-Escalation Trial
Objective: To explore intrathecal administration of autologous mesenchymal stem cells (MSCs) as therapeutic approach to multiple system atrophy (MSA). Background: MSA is a rapidly progressive…Systematic literature review of droxidopa in clinical trials for neurogenic orthostatic hypotension (nOH) in parkinsonism
Objective: The aim of this study was to review the published evidence for the efficacy, safety, and dosing practices of droxidopa treatment for symptomatic neurogenic…Reducing C-terminal truncation mitigates synucleinopathy and neurodegeneration in a transgenic model of multiple system atrophy
Objective: To assess the therapeutic efficacy of the caspase-1 inhibitor prodrug VX-765 on alpha-synuclein (α-syn) pathology and neuroprotection in a transgenic mouse model of multiple…Glucagon-like peptide 1 analogues for treating multiple system atrophy: A translational study
Objective: (i) To determine whether insulin resistance is a neuropathological feature of multiple system atrophy (MSA) and, (ii), to evaluate the therapeutic efficacy of the…Deep brain stimulation may lead to dramatic worsening of slowly progressive multiple system atrophy: A clinico-pathological series and review of the literature
Objective: The aim of the present study is to describe one of the largest series of histologically proven multiple system atrophy (MSA) patients, who underwent…
- « Previous Page
- 1
- …
- 5
- 6
- 7